A detailed history of Citigroup Inc transactions in Immunic, Inc. stock. As of the latest transaction made, Citigroup Inc holds 108,187 shares of IMUX stock, worth $114,678. This represents 0.0% of its overall portfolio holdings.

Number of Shares
108,187
Holding current value
$114,678
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.08 - $1.95 $116,841 - $210,964
108,187 New
108,187 $178,000
Q3 2022

Nov 10, 2022

SELL
$3.0 - $5.49 $864 - $1,581
-288 Reduced 46.91%
326 $1,000
Q2 2022

Aug 10, 2022

SELL
$3.13 - $12.25 $2,478 - $9,702
-792 Reduced 56.33%
614 $2,000
Q1 2022

May 12, 2022

SELL
$9.54 - $14.26 $39,295 - $58,736
-4,119 Reduced 74.55%
1,406 $16,000
Q4 2021

Feb 10, 2022

BUY
$7.34 - $10.25 $11,332 - $15,826
1,544 Added 38.78%
5,525 $53,000
Q3 2021

Nov 10, 2021

BUY
$8.05 - $13.29 $32,047 - $52,907
3,981 New
3,981 $35,000

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $32.4M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.